Policy Press

Publishing with a purpose

Gangs, Drugs and (Dis)Organised Crime

By Robert McLean

Published

Aug 21, 2019

Page count

256 pages

ISBN

978-1529203028

Dimensions

234 x 156 mm

Imprint

Bristol University Press

Published

Aug 21, 2019

Page count

256 pages

ISBN

978-1529203042

Dimensions

Imprint

Bristol University Press

Published

Aug 21, 2019

Page count

256 pages

ISBN

978-1529203042

Dimensions

Imprint

Bristol University Press
Gangs, Drugs and (Dis)Organised Crime

Drawing upon unique empirical data based on interviews with high-profile ex-offenders and experts, this book sheds new light on drug markets and gangs in the UK. The study shows how traditional methods of tackling gang violence fail to address the intertwined nature of those criminal activities which can overlap with other organised crime spheres. McLean sparks new debate on the subject, offering solutions and alternatives.

“…[A] fine, courageous book. Reading McLean’s personal account and research reminds this reviewer of the randomness of the luck and context surrounding youths and gangs. Certainly here in the United States, “one zip code over”...can mean the difference between a life a la McLean’s Young Teams and, say, incredible opportunity and resources where the sky is indeed the limit.” Criminal Law and Criminal Justice Books

''A well-written and fascinating ethnography which provides a holistic and nuanced description of Scottish gangs and drug markets. Should be essential reading for students, academics, practitioners and policy makers in Scotland and beyond.'' James Windle, University College Cork

Robert McLean is a lecturer within the Interdisciplinary Research Unit on Crime, Policing and Social Justice at the University of the West of Scotland.

Preface

Part I

Introduction

Part II

A Review of Gang Literature

Scottish Gang Literature

Part III

Rediscovering Scottish Gangs: Towards a Typology

Street Life, Crime, and (Dis)Organised Crime

Gangs and Drug Supply

Part IV

Tackling Gangs, Organised Crime, and Rethinking Drug Policy